[{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"AAV-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"INVO Bioscience \/ NAYA Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ NAYA Biosciences"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"AAV-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"INVO Bioscience \/ NAYA Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"INVO Bioscience \/ NAYA Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by INVO Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy (LHON).

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 14, 2024

                          Lead Product(s) : AAV-based Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Naya Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : AAV-based Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Naya Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank